Microbot Medical Inc. has signed a Letter of Agreement with Sanmina Corporation, a global manufacturing solutions provider. This partnership is intended to expand Microbot's manufacturing capacity for its LIBERTY Endovascular Robotic System. The agreement supports the company's cost reduction strategy and aims to improve operating efficiencies and lower costs. Sanmina's global presence may benefit Microbot as it scales production to meet anticipated demand. The move is driven by increasing demand in the U.S. and growing momentum in international markets, including recent clearance in Israel and progress towards CE Mark.